Core Viewpoint - Jiuzhou Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 46.67% but a recent decline in the last five trading days by 3.30% [1] Financial Performance - For the period from January to September 2025, Jiuzhou Pharmaceutical achieved a revenue of 4.16 billion yuan, representing a year-on-year growth of 4.92% [2] - The net profit attributable to the parent company for the same period was 748 million yuan, showing an increase of 18.51% year-on-year [2] Stock Market Activity - As of November 5, Jiuzhou Pharmaceutical's stock price was 19.34 yuan per share, with a market capitalization of 17.202 billion yuan [1] - The stock has seen a net outflow of main funds amounting to 21.4868 million yuan, with significant selling pressure observed [1] Shareholder Information - As of September 30, 2025, the number of Jiuzhou Pharmaceutical's shareholders increased to 59,200, up by 10.22% from the previous period [2] - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited holding 20.368 million shares, an increase of 7.8125 million shares [3] Dividend Distribution - Jiuzhou Pharmaceutical has distributed a total of 2.183 billion yuan in dividends since its A-share listing, with 1.245 billion yuan distributed over the last three years [3]

证券代码：603456 证券简称：九洲药业 公告编号：2025-063 浙江九洲药业股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 10 月 31 日 (二)股东大会召开的地点：浙江九洲药业股份有限公司会议室（浙江省台州市椒 江区外沙路 99 号） | 1、出席会议的股东和代理人人数 | 524 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 425,977,164 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 48.31 | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由董事长花莉蓉女士主持，会议召集、召开及表决方式符合《公 司法》等有关法律法规和《公司章程》的规定。 (五)公司董事、监事和董事会秘书的出席情况 二、 议案审议情况 (一 ...

浙江天册律师事务所 关于 浙江九洲药业股份有限公司 2025 年第一次临时股东大会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 0 法律意见书 浙江天册律师事务所 关于 浙江九洲药业股份有限公司 2025 年第一次临时股东大会的 法律意见书 编号：TCYJS2025H1774 号 致：浙江九洲药业股份有限公司 浙江天册律师事务所（以下简称"本所"）接受浙江九洲药业股份有限公司（以 下简称"九洲药业"或"公司"）的委托，指派本所律师参加公司 2025 年第一次 临时股东大会，并根据《中华人民共和国证券法》（以下简称"《证券法》"）、 《中华人民共和国公司法》（以下简称"《公司法》"）和《上市公司股东会规则》 （以下简称"《股东会规则》"）等法律、法规和有关规范性文件，以及《浙江九 洲药业股份有限公司章程》（以下简称"《公司章程》"）的有关规定，出具本法律意 见书。 在本法律意见书中，本所律师仅对本次股东大会召集、召开程序、出席人员的 资格、召集人的资格、表决程序及表决结果的合法有效性发表意见，不对会议所 ...

Core Viewpoint - Jiuzhou Pharmaceutical is a well-established manufacturer of chemical raw materials and pharmaceutical intermediates in China, with strong technical capabilities and scale advantages in the custom drug development and production service sector [1] Financial Performance - In Q3 2025, Jiuzhou Pharmaceutical reported a revenue of 4.16 billion yuan, ranking 5th in the industry out of 29 companies, surpassing the industry average of 2.547 billion yuan and the median of 607 million yuan, but still lagging behind the top competitors WuXi AppTec at 32.857 billion yuan and Kanglong Chemical at 10.086 billion yuan [2] - The company's net profit for the same period was 749 million yuan, also ranking 5th in the industry, above the average of 585 million yuan but below the median of 80.706 million yuan, with WuXi AppTec leading at 12.206 billion yuan and Tigermed at 1.092 billion yuan [2] Financial Ratios - As of Q3 2025, Jiuzhou Pharmaceutical's debt-to-asset ratio was 17.67%, down from 21.67% year-on-year and below the industry average of 22.79%, indicating lower debt pressure [3] - The gross profit margin for Q3 2025 was 37.55%, an increase from 34.75% year-on-year, and close to the industry average of 37.70%, reflecting improved profitability [3] Executive Compensation - The chairman, Hua Lirong, received a salary of 1.985 million yuan in 2024, a decrease of 528,000 yuan from 2023 [4] - The president, Mei Yijiang, earned 3.276 million yuan in 2024, down 339,000 yuan from the previous year [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 10.22% to 59,200, while the average number of shares held per shareholder decreased by 9.27% to 15,000 [5] - Major shareholders include Hong Kong Central Clearing Limited and various mutual funds, with notable increases in holdings from some shareholders [5] Business Highlights - The CDMO business continues to grow rapidly, driven by strong overseas demand and an increase in key clinical batches and NDA projects [5][6] - The TIDES business is progressing well, with the second phase of peptide production capacity set to launch [5][6] - The company is expanding its global footprint, with significant growth in the Japanese, Korean, and U.S. markets [5] Future Projections - Revenue forecasts for Jiuzhou Pharmaceutical are 5.57 billion yuan, 5.83 billion yuan, and 6.29 billion yuan for 2025, 2026, and 2027 respectively, with net profits projected at 949 million yuan, 1.052 billion yuan, and 1.207 billion yuan for the same years [5][6]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 现金管理受托方：中国农业银行股份有限公司常熟经济开发区支行（以 下简称"农业银行常熟经济开发区支行"）； 履行的审议程序：浙江九洲药业股份有限公司（以下简称"公司"、"九洲 药业"）于 2024 年 12 月 13 日召开的第八届董事会第十一次会议、第八届监事会 第七次会议，审议通过了《关于使用闲置募集资金进行现金管理的议案》，同意 公司及子公司在保障资金安全及确保不影响募集资金投资项目建设和使用计划 的前提下，使用不超过人民币 12 亿元的闲置募集资金适时购买安全性高、流动 性好的投资产品（包括但不限于结构性存款、定期存款、大额存单、通知存款、 收益凭证及银行或券商理财产品等），且该等投资产品不得用于质押，不用于以 证券投资为目的的投资行为。期限为自董事会审议通过之日起不超过 12 个月， 单笔投资产品的期限不超过 12 个月。本事项无需提交股东大会审议。具体内容 详见公司于 2024 年 12 月 14 日在上海证券交易所网站（www.sse.com）和《上海 ...

Core Viewpoint - The medical innovation sector is experiencing a structural recovery, with significant inflows into the Medical Innovation ETF and positive performance from key companies in the sector [1][2]. Group 1: Market Performance - On October 29, the Medical Innovation ETF (516820.SH) fell by 1.28%, with component stocks showing mixed results; Chuaning Biological (301301) led gains at 5.12%, while Ailis (688578) saw the largest decline at 5.13% [1]. - The Medical Innovation ETF has seen continuous net inflows over the past five days, with a peak single-day net inflow of 38.68 million yuan, totaling 66.42 million yuan and an average daily net inflow of 13.28 million yuan [1]. Group 2: Industry Trends - The pharmaceutical sector has undergone a prolonged valuation adjustment, but a significant structural recovery trend has emerged recently, supported by policies promoting commercial insurance development [1]. - The investment and financing landscape in the pharmaceutical sector is expected to recover, driven by a rebound in the secondary market, with continued positive sentiment in the CXO and upstream segments [1]. - Recent quarterly reports from several CXO companies, including WuXi AppTec, Tigermed, and others, indicate a positive outlook for the industry [1]. Group 3: Future Outlook - The CXO sector continues to show strong performance, with companies like WuXi AppTec and Boteng surpassing expectations in their quarterly results [2]. - The innovative drug sector is on a long-term upward trend, with opportunities arising from both domestic revenue growth and international expansion [2]. - The expectation of interest rate cuts in the U.S. is likely to enhance global liquidity and support the trend in technology stocks, providing an opportunity for investors to capitalize on the rebound in core pharmaceutical assets through the Medical Innovation ETF [2].

Core Viewpoint - The CRO index experienced a strong performance on October 24, with an intraday increase of 2.01% [1] Group 1: Index Performance - The CRO index saw a day-on-day increase of 2.01% [1] Group 2: Component Stocks - Most component stocks rose, with Boten Co., Ltd. leading the gains at 5.40% [1] - Jiuzhou Pharmaceutical increased by 4.52% [1] - Bid Pharma rose by 4.31% [1] - Haoyuan Pharmaceutical followed with a 4.15% increase [1] - Kanglong Chemical achieved a rise of 3.59% [1]

Core Viewpoint - The pharmaceutical and biotechnology industry is showing strong performance in Q3, with several companies reporting significant year-on-year growth in net profit, particularly in the traditional Chinese medicine sector and contract research organizations (CROs) [1][2][6]. Group 1: Company Performance - Over 50 pharmaceutical and biotechnology companies have disclosed their Q3 reports, with Teva Pharmaceutical, Fujilay, and Wohua Pharmaceutical leading in net profit growth rates of 985.18%, 430.16%, and 179.34% respectively [1][2]. - Teva Pharmaceutical reported a revenue of 692 million yuan, a 51.86% increase year-on-year, with net profit reaching 65.2 million yuan, up 985.18% [2]. - Wohua Pharmaceutical achieved a revenue of 625 million yuan, an 8.31% increase, with a net profit of 63.99 million yuan, reflecting a 179.34% growth [2]. Group 2: Industry Trends - The CRO and CDMO sectors are expected to continue their positive performance from the first half of the year, with several segments like traditional Chinese medicine, medical devices, and raw materials also showing good results [1][6]. - Companies like Mindray Medical anticipate a positive growth trajectory in both domestic and international markets, with expectations of improved revenue from Q3 onwards [4]. - The overall demand in the domestic pharmaceutical market is gradually recovering, particularly in early-stage research and development [5]. Group 3: Future Outlook - Analysts are optimistic about the innovation drug sector, which is expected to maintain high revenue growth and continue to reduce losses, with a focus on companies showing signs of performance improvement [6][7]. - The market is advised to pay attention to segments like medical devices and traditional Chinese medicine, which are projected to rebound in 2025 [7].

Core Viewpoint - The pharmaceutical and biotechnology industry is showing strong performance in Q3, with several companies reporting significant year-on-year growth in net profit, particularly in the traditional Chinese medicine sector and contract research organizations (CROs) [1][2][6]. Group 1: Company Performance - Special One Pharmaceutical reported a net profit growth of 985.18% year-on-year for the first three quarters, with revenue reaching 692 million yuan, a 51.86% increase [2]. - WoHua Pharmaceutical achieved a net profit growth of 179.34%, with revenue of 625 million yuan, reflecting an 8.31% increase [2]. - Other companies like LiSheng Pharmaceutical and Guangzheng Ophthalmology also reported net profit growth exceeding 100% [1]. Group 2: Industry Trends - The CRO and CDMO sectors are expected to continue their positive performance from the first half of the year, with strong demand anticipated [1][6]. - The Chinese medicine, medical device, raw material drug, and pharmacy sectors are also showing promising results, with several companies reporting substantial growth [1][6]. - The market is shifting towards innovative drugs, with a focus on companies that are experiencing turning points in their performance [6][7]. Group 3: Market Outlook - Companies like Mindray Medical expect revenue growth in the international market to accelerate, supported by ongoing localization efforts [4]. - The demand for CDMO services is optimistic, with increased capacity utilization and a rise in new client projects [5]. - Analysts suggest that the innovative drug sector will remain a key investment focus, with expectations of continued high revenue growth and improved profitability [6][7].

Core Viewpoint - The pharmaceutical and biotechnology industry is showing strong performance in Q3, with several companies reporting significant year-on-year growth in net profit, particularly in the traditional Chinese medicine sector and contract research organizations (CRO) [1][2][5]. Industry Performance - Over 50 pharmaceutical and biotechnology companies have disclosed their Q3 reports, with notable net profit growth rates: Teva Pharmaceutical at 985.18%, Fushilai at 430.16%, and Wohua Pharmaceutical at 179.34% [1]. - Companies like Hualan Biological Engineering and Sanofi have also reported substantial growth, with net profit increases exceeding 60% [1]. Company Highlights - Teva Pharmaceutical reported Q3 revenue of 692 million yuan, a 51.86% increase year-on-year, with net profit reaching 65.2 million yuan, up 985.18% [2]. - Wohua Pharmaceutical achieved Q3 revenue of 625 million yuan, an 8.31% increase, with net profit of 63.9 million yuan, up 179.34% [2]. - Heavy Drug Holdings expects a net profit of 358 to 400 million yuan for the first three quarters of 2025, representing a year-on-year growth of 22.51% to 36.88% [2]. Market Trends - The CRO and CDMO sectors are expected to continue their positive performance from the first half of the year, with strong demand anticipated in the coming quarters [3][5]. - Companies are actively expanding into international markets, with expectations of revenue growth driven by improved local market conditions and ongoing business development transactions [3][4]. Future Outlook - Analysts suggest that the innovation drug sector remains a key investment focus, with expectations of continued high revenue growth and a shift in market dynamics favoring companies with improving performance [5][6]. - The medical device sector, particularly home medical devices, is also expected to stabilize and recover in Q4 2025, alongside opportunities in aging and outpatient consumption areas [6].